Antibody-directed enzyme prodrug therapy (ADEPT) has the potential of greatly enhancing
antitumor selectivity of cancer therapy by synthesizing chemotherapeutic agents selectively
at tumor sites. This therapy is based upon targeting a prodrug-activating enzyme to a tumor
by attaching the enzyme to a tumor-selective antibody and dosing the enzyme-antibody
conjugate systemically. After the enzyme-antibody conjugate is localized to the tumor, the
prodrug is then also dosed systemically, and the previously targeted enzyme converts it to …